MannKind Corp (MNKD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:MannKind Corp (MNKD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014271
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MannKind Corp (MannKind) is a biopharmaceutical company that discovers, develops and commercializes therapeutic products to treat diseases such as diabetes. The company’s lead product, Afrezza is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. It also developed a line of breath-powered, dry powder inhalers. Mannkind develops its products based on Technosphere drug delivery platform, its proprietary formulation technology. It also utilizes inhalation profiling technologies such as BluHale. It conducts its manufacturing operations in Danbury, Connecticut and sells its products in the US through a direct sales force. MannKind is headquartered in California, the US.

MannKind Corp (MNKD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
MannKind Corp, Medical Devices Deals, 2011 to YTD 2017 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MannKind Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MannKind and Biomm Enter into Distribution Agreement 12
MannKind Partners with JDRF 13
Licensing Agreements 14
Receptor Life Sciences Enters into Licensing Agreement with MannKind 14
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 15
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 17
Equity Offering 18
Mannkind to Raise USD61 Million in Private Placement of Shares 18
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 20
MannKind Raises USD36.2 Million in Private Placement of Shares 21
Mannkind Raises USD50 Million in Private Placment of Shares 22
MannKind Announces Public Offering Of Common Stock For US$50 Million 24
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 25
MannKind Completes Public Offering Of Units For US$86 Million 27
Debt Offering 29
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 29
MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For US$370 Million 31
MannKind Corp – Key Competitors 32
MannKind Corp – Key Employees 33
MannKind Corp – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Nov 07, 2017: MannKind Reports 2017 Third Quarter Financial Results 35
Aug 07, 2017: MannKind Reports 2017 Second Quarter Financial Results 37
May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 39
Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 40
Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results 42
Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results 44
May 09, 2016: MannKind Reports 2016 First Quarter Financial Results 45
Mar 14, 2016: MannKind Reports 2015 Fourth Quarter and Full Year Financial Results 46
Corporate Communications 47
Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer 47
Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer 48
Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 49
Feb 19, 2016: Alfred Mann Steps Down as Executive Chairman of Mannkind 50
Jan 11, 2016: MannKind Provides Update on Senior Management 51
Product News 52
08/01/2016: Mannkind Assumes Responsibility for Distribution of Afrezza and Launches Patient Reimbursement and Adherence Support Programs 52
06/12/2016: MannKind Announces Late-Breaking Data Demonstrating Faster Onset and Shorter Duration of Action Compared to Mealtime Insulins 53
Mar 08, 2017: MannKind and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes 55
02/01/2017: MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth 56
Other Significant Developments 57
Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
MannKind Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MannKind Corp, Deals By Therapy Area, 2011 to YTD 2017 9
MannKind Corp, Medical Devices Deals, 2011 to YTD 2017 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MannKind and Biomm Enter into Distribution Agreement 12
MannKind Partners with JDRF 13
Receptor Life Sciences Enters into Licensing Agreement with MannKind 14
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 15
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 17
Mannkind to Raise USD61 Million in Private Placement of Shares 18
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 20
MannKind Raises USD36.2 Million in Private Placement of Shares 21
Mannkind Raises USD50 Million in Private Placment of Shares 22
MannKind Announces Public Offering Of Common Stock For US$50 Million 24
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 25
MannKind Completes Public Offering Of Units For US$86 Million 27
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 29
MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For US$370 Million 31
MannKind Corp, Key Competitors 32
MannKind Corp, Key Employees 33
MannKind Corp, Other Locations 34

★海外企業調査レポート[MannKind Corp (MNKD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TransAlta Corporation:発電所・企業SWOT分析
    TransAlta Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employe …
  • An Binh Commercial Joint Stock Bank:企業の戦略的SWOT分析
    An Binh Commercial Joint Stock Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Bharat Heavy Electricals Ltd (BHEL)-エネルギー分野:企業M&A・提携分析
    Summary Bharat Heavy Electricals Limited (BHEL) is an integrated power plant equipment manufacturer that designs, manufactures, constructs, tests, commissions and services a broad range of products. Its product portfolio includes transformers, valves and oil field equipment, electrostatic precipitat …
  • CPFL Energia SA:発電所・企業SWOT分析
    CPFL Energia SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (ex …
  • Celsense Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Celsense Inc (Celsense) is a biotechnology company that develops magnetic resonance imaging detection products to monitor the location and quantity of transplanted cells. The company’s products include v-sense, cell sense and voxel tracker. Its v-sense product is a reagent used to detect var …
  • Select Medical Holdings Corp (SEM):企業の財務・戦略的SWOT分析
    Summary Select Medical Holdings Corp (SMHC) is a healthcare service provider that offers outpatient rehabilitation services. The center provides long-term acute care services such as cardiac services, infectious disease treatment, medically complex treatment, neuro or post-trauma, pulmonary or venti …
  • Helmerich & Payne Inc (HP):企業の財務・戦略的SWOT分析
    Helmerich & Payne Inc (HP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nippon Soda Co Ltd (4041):企業の財務・戦略的SWOT分析
    Nippon Soda Co Ltd (4041) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Golden Gate Capital:企業の戦略的SWOT分析
    Golden Gate Capital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Hong Leong Group:企業の戦略・SWOT・財務情報
    Hong Leong Group - Strategy, SWOT and Corporate Finance Report Summary Hong Leong Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Bank of the West:企業の戦略・SWOT・財務情報
    Bank of the West - Strategy, SWOT and Corporate Finance Report Summary Bank of the West - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Kimal plc-医療機器分野:企業M&A・提携分析
    Summary Kimal plc (Kimal) is a medical equipment company that develops, manufactures and markets customised procedure packs and vascular access devices. The company’s products include soft tissue biopsy needles, bone marrow biopsy needles, catheter accessories, catheter lock solution, closure device …
  • Bunzl plc (BNZL):企業の財務・戦略的SWOT分析
    Bunzl plc (BNZL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Television Francaise 1 SA (TFI):企業の財務・戦略的SWOT分析
    Television Francaise 1 SA (TFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • First Majestic Silver Corp:企業の戦略・SWOT・財務情報
    First Majestic Silver Corp - Strategy, SWOT and Corporate Finance Report Summary First Majestic Silver Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Reach Subsea ASA (REACH):企業の財務・戦略的SWOT分析
    Reach Subsea ASA (REACH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • AbbVie Inc (ABBV):企業の財務・戦略的SWOT分析
    AbbVie Inc (ABBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Santhera Pharmaceuticals Holding AG (SANN):製薬・医療:M&Aディール及び事業提携情報
    Summary Santhera Pharmaceuticals Holding AG (Santhera) develops and commercializes novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. It specifically focuses in the area of neuromuscular and neuro-ophthalmological conditions. The company’s lead produc …
  • Itochu Corporation (8001)-石油・ガス分野:企業M&A・提携分析
    Summary Itochu Corporation (Itochu) is a trading company. It offers domestic trading, import and export, and overseas trading. The company trades in products such as textile, machinery, metals, minerals, energy, chemicals, food, general products, information and communications technology, realty, in …
  • Puma Energy Holdings Pte Ltd:企業の戦略的SWOT分析
    Puma Energy Holdings Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆